Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Cancer · 2026

Decnupaz (pivekimab sunirine-pvzy)

The FDA approved Decnupaz (pivekimab sunirine-pvzy) on May 27, 2026 to treat adults with blastic plasmacytoid dendritic cell neoplasm.
Brand name
Decnupaz
Generic name
pivekimab sunirine-pvzy
FDA approval date
May 27, 2026
Approved use (FDA wording)
To treat adults with blastic plasmacytoid dendritic cell neoplasm
Company
Abbvie Inc.
Application
BLA761460
Dosage form / route
VIAL · SINGLE-DOSE
Boxed warning on label
Yes (see the FDA label)
Category on this site
Cancer

Indications and usage, from the FDA label

1. INDICATIONS AND USAGE DECNUPAZ is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). DECNUPAZ is a CD123-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). ( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.